Clinical trial
A Phase 2 Study of ANC-501 in the Treatment of Adults With Major Depressive Disorder
NCT05439603 is registered in ClinicalTrials.gov with Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of ANC-501 in the Treatment of Adults With Major Depressive Disorder
- Lead sponsor
- Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 19, 2022
- Completion date
- October 18, 2023
- Enrollment
- 15 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.